SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation

OBJECTIVES: Humoral and cellular immunity to SARS‐CoV‐2 following COVID‐19 will likely contribute to protection from reinfection or severe disease. It is therefore important to characterise the initiation and persistence of adaptive immunity to SARS‐CoV‐2 amidst the ongoing pandemic. METHODS: Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandberg, John Tyler, Varnaitė, Renata, Christ, Wanda, Chen, Puran, Muvva, Jagadeeswara R, Maleki, Kimia T, García, Marina, Dzidic, Majda, Folkesson, Elin, Skagerberg, Magdalena, Ahlén, Gustaf, Frelin, Lars, Sällberg, Matti, Eriksson, Lars I, Rooyackers, Olav, Sönnerborg, Anders, Buggert, Marcus, Björkström, Niklas K, Aleman, Soo, Strålin, Kristoffer, Klingström, Jonas, Ljunggren, Hans‐Gustaf, Blom, Kim, Gredmark‐Russ, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256672/
https://www.ncbi.nlm.nih.gov/pubmed/34257967
http://dx.doi.org/10.1002/cti2.1306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256672/
https://www.ncbi.nlm.nih.gov/pubmed/34257967
http://dx.doi.org/10.1002/cti2.1306

Ejemplares similares